This company has been acquired
Satsuma Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Satsuma Pharmaceuticals's earnings have been declining at an average annual rate of -33.2%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually.
Key information
-33.2%
Earnings growth rate
46.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -172.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Can Satsuma Pharmaceuticals (NASDAQ:STSA) Afford To Invest In Growth?
Feb 15
Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?
Sep 02Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation
May 13Satsuma Pharmaceuticals: Sizing Up This One Trick Pony
Nov 07Satsuma shares surge on data from early-stage STS101 trial
Jun 16Do Institutions Own Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Shares?
Jan 26Revenue & Expenses BreakdownBeta
How Satsuma Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -65 | 14 | 40 |
| 31 Dec 22 | 0 | -70 | 15 | 44 |
| 30 Sep 22 | 0 | -62 | 16 | 47 |
| 30 Jun 22 | 0 | -61 | 15 | 46 |
| 31 Mar 22 | 0 | -56 | 14 | 42 |
| 31 Dec 21 | 0 | -51 | 14 | 38 |
| 30 Sep 21 | 0 | -48 | 13 | 35 |
| 30 Jun 21 | 0 | -47 | 14 | 33 |
| 31 Mar 21 | 0 | -46 | 13 | 34 |
| 31 Dec 20 | 0 | -48 | 12 | 36 |
| 30 Sep 20 | 0 | -46 | 11 | 36 |
| 30 Jun 20 | 0 | -42 | 8 | 35 |
| 31 Mar 20 | 0 | -37 | 7 | 32 |
| 31 Dec 19 | 0 | -28 | 5 | 24 |
| 30 Sep 19 | 0 | -20 | 3 | 17 |
| 30 Jun 19 | 0 | -13 | 2 | 11 |
| 31 Mar 19 | 0 | -8 | 1 | 7 |
| 31 Dec 18 | 0 | -7 | 1 | 6 |
Quality Earnings: STSA is currently unprofitable.
Growing Profit Margin: STSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STSA is unprofitable, and losses have increased over the past 5 years at a rate of 33.2% per year.
Accelerating Growth: Unable to compare STSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STSA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.3%).
Return on Equity
High ROE: STSA has a negative Return on Equity (-172.21%), as it is currently unprofitable.